Nurgül Sevimli1, Dilek Yapar2, Haluk Türktaş1. 1. Department of Chest Diseases, Gazi University School of Medicine, Ankara, Turkey. 2. Department of Public Health, Gazi University School of Medicine, Ankara, Turkey.
Abstract
OBJECTIVES: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is defined as a persistent airflow limitation with features of both asthma and COPD. However, in Turkey, there are limited data about ACO. The aims of the present study were to determine the prevalence of ACO among patients with asthma, to compare the clinical characteristics of patients with ACO and asthma, and to determine the threshold values for the diagnosis of ACO. MATERIALS AND METHODS: The study group comprised 338 patients admitted to the outpatient clinics between 2010 and 2017 and who had undergone at least three pulmonary function tests within the last 2 years. Patients aged >40 years with a smoking history of >10 pack-years or biomass exposure, with at least three features of both diseases, and with reversible and persistent airflow limitation were diagnosed with ACO. The study is a retrospective study so we did not get informed concent. RESULTS: Asthma-chronic obstructive pulmonary disease overlap was diagnosed in 40 (11.8%) patients. Patients with ACO had fewer allergic comorbidities, worse spirometric parameters, and required higher doses of inhaled corticosteroids than patients with asthma only (p<0.05). No significant differences were observed between the groups regarding survival or number of hospitalizations and attacks (p>0.05). Threshold values were determined as age ≥57.5 years, smoking history ≥14 pack-years, and diagnosis at age ≥40.5 years. CONCLUSION: The frequency of ACO was observed to be very high in patients with asthma. In patients >57.5 years old, with a smoking history of >14.5 pack-years, and diagnosed with asthma at >40.5 years old, the probability of ACO diagnosis increases.
OBJECTIVES:Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is defined as a persistent airflow limitation with features of both asthma and COPD. However, in Turkey, there are limited data about ACO. The aims of the present study were to determine the prevalence of ACO among patients with asthma, to compare the clinical characteristics of patients with ACO and asthma, and to determine the threshold values for the diagnosis of ACO. MATERIALS AND METHODS: The study group comprised 338 patients admitted to the outpatient clinics between 2010 and 2017 and who had undergone at least three pulmonary function tests within the last 2 years. Patients aged >40 years with a smoking history of >10 pack-years or biomass exposure, with at least three features of both diseases, and with reversible and persistent airflow limitation were diagnosed with ACO. The study is a retrospective study so we did not get informed concent. RESULTS:Asthma-chronic obstructive pulmonary disease overlap was diagnosed in 40 (11.8%) patients. Patients with ACO had fewer allergic comorbidities, worse spirometric parameters, and required higher doses of inhaled corticosteroids than patients with asthma only (p<0.05). No significant differences were observed between the groups regarding survival or number of hospitalizations and attacks (p>0.05). Threshold values were determined as age ≥57.5 years, smoking history ≥14 pack-years, and diagnosis at age ≥40.5 years. CONCLUSION: The frequency of ACO was observed to be very high in patients with asthma. In patients >57.5 years old, with a smoking history of >14.5 pack-years, and diagnosed with asthma at >40.5 years old, the probability of ACO diagnosis increases.
Authors: Ana Maria B Menezes; Maria Montes de Oca; Rogelio Pérez-Padilla; Gilbert Nadeau; Fernando César Wehrmeister; Maria Victorina Lopez-Varela; Adriana Muiño; José Roberto B Jardim; Gonzalo Valdivia; Carlos Tálamo Journal: Chest Date: 2014-02 Impact factor: 9.410
Authors: Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Jesús Molina; Pere Almagro; José Antonio Quintano; Juan Antonio Riesco; Juan Antonio Trigueros; Pascual Piñera; Adolfo Simón; Juan Luis Rodríguez-Hermosa; Esther Marco; Daniel López; Ramon Coll; Roser Coll-Fernández; Miguel Ángel Lobo; Jesús Díez; Joan B Soriano; Julio Ancochea Journal: Arch Bronconeumol Date: 2014-01 Impact factor: 4.872
Authors: Marc Miravitlles; Joan B Soriano; Julio Ancochea; Luis Muñoz; Enric Duran-Tauleria; Guadalupe Sánchez; Víctor Sobradillo; Francisco García-Río Journal: Respir Med Date: 2013-04-16 Impact factor: 3.415
Authors: Denis E O'Donnell; Shaw Aaron; Jean Bourbeau; Paul Hernandez; Darcy D Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Rogers Goldstein; Rick Hodder; Alan Kaplan; Sean Keenan; Yves Lacasse; Francois Maltais; Jeremy Road; Graeme Rocker; Don Sin; Tasmin Sinuff; Nha Voduc Journal: Can Respir J Date: 2007-09 Impact factor: 2.409
Authors: Heidi Andersén; Pekka Lampela; Antti Nevanlinna; Olli Säynäjäkangas; Timo Keistinen Journal: Clin Respir J Date: 2013-03-20 Impact factor: 2.570
Authors: Roberto de Marco; Giancarlo Pesce; Alessandro Marcon; Simone Accordini; Leonardo Antonicelli; Massimiliano Bugiani; Lucio Casali; Marcello Ferrari; Gabriele Nicolini; Maria Grazia Panico; Pietro Pirina; Maria Elisabetta Zanolin; Isa Cerveri; Giuseppe Verlato Journal: PLoS One Date: 2013-05-10 Impact factor: 3.240